Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
On page 1212, in the last sentence of the first paragraph, the sentence should read: The titer of Oka/Merck
varicella-zoster virus is higher in MMRV vaccine than in single antigen varicella vaccine,
VARIVAX® (Merck), a minimum of
3.99 log10 plaque-forming units (pfu) versus 1,350 pfu (approximately
3.13 log10), respectively.
On page 1213, under "Indications and Usage," No. 1, the last sentence should read: MMRV vaccine can reduce
the number of injections when administered to children aged
12 months--12 years for whom 1) the first doses of MMR
and varicella vaccines are indicated and 2) the second dose of MMR and either the first or second dose (e.g., during a
varicella outbreak) of varicella vaccine are indicated. MMRV vaccine is administered subcutaneously as a single 0.5-mL dose.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
